JAMA Community Open has revealed a brand new examine demonstrating respiratory syncytial virus (RSV) vaccine effectiveness in adults 60 and older of 90% for each RSV–associated hospitalization and emergency division (ED) visits.
The examine offers real-world VE information based mostly on the 2023-24 RSV season and outcomes seen amongst adults aged 60 years or older with hospitalizations or ED visits at Kaiser Permanente of Southern California from November 24, 2023, to April 9, 2024.
All members had respiratory swabs collected and examined for RSV. Although earlier trials have proven excessive VE, most trialed adults had been 75 years or older. RSVpreF (Abrysvo) vaccine receipt throughout the first RSV season after licensure, and 21 or extra days earlier than the sickness occasion was the principle evaluation.
Abrysvo was authorized to be used in america in June 2023 as a single-dose vaccine meant to guard older adults from extreme RSV infections.
In whole 7,047 decrease respiratory tract illness hospitalizations or ED encounters with RSV testing outcomes had been included within the examine. Sufferers had a mean age of 76.8 years, 54.2% had been ladies, 33.0% had been Hispanic, and 36.9% had been non-Hispanic White.
90% VE throughout first season
Fourteen p.c of sufferers had been immunocompromised. Total, 8.8% (623 of seven,047) examined constructive for RSV, and three.2% (223 of seven,047) acquired RSVpreF. Amongst 6,424 test-negative controls, 221 (3.4%) had been vaccinated.
When RSVpreF was acquired a mean of 58 days earlier than sickness, the adjusted VE when the authors used broad controls was 90% (95% confidence interval [CI]59% to 97%). It was 91% (95% CI, 59% to 98%) once they used strict controls. The efficacy held via 5 months of follow-up.
For about each 250 individuals vaccinated, 1 RSV-related ED or hospitalization encounter might be prevented within the first season after vaccination.
“Primarily based on our examine outcomes and RSV incidence in older adults, for about each 250 individuals vaccinated, 1 RSV-related ED or hospitalization encounter might be prevented within the first season after vaccination,” the authors wrote. “These information counsel use of RSVpreF in older adults, offering a chance to scale back extreme medically attended RSV illness burden.”
RSV causes a big burden of illness for US adults. Every year roughly 160,000 RSV-related acute respiratory an infection hospitalizations and 120,000 ED visits are associated to the virus.
